PDS Biotechnology Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PDSB | CHRS | CGEN | APLM | MOLN | PYXS | |
|---|---|---|---|---|---|---|
| Market cap | 110.16M | 159.14M | 196.08M | 62.15M | 145.18M | 240.11M |
| P/E (TTM) | — | — | 5.4 | — | — | — |
| Forward P/E | -4.4 | -1.6 | -5.6 | -32.8 | -23.4 | -1.8 |
| Price/book | -23.7 | 2.6 | 2.2 | -14.4 | 2.0 | 11.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +44.35% | −38.15% | −4.91% | +15.66% | +1.58% | −41.16% |
| Today | +10.14% | −3.74% | −2.82% | −0.84% | −1.56% | −0.99% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PDSB news ›9 Hepatobiliary Cancer Trials to Watch at ESMO 2026
This overview highlights 9 HCC and biliary tract cancer trials to watch at ESMO 2026. Abstract: LBA48 Presenter: Masatoshi Kudo (Osaka, Japan) Trial Type: Phase III Session: Proffered Paper session At ESMO 2026, EMERALD-3 will report liver…
PDS announces publication of results from Phase 2 trial of PDS0101
PDS Biotechnology (PDSB) announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in comb... PDS announces publication of results from Phase 2 trial of PDS0101 PDS Biotechnology (PDSB)…
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’
Shares of ImmunityBio, Inc. (IBRX) climbed about 6% in premarket trading on Tuesday after the Saudi Food and Drug Authority (SFDA) encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin (rBCG), a…
Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement
TradingKey Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement What is driving Immunitybio Inc (IBRX)’s stock price up today? ImmunityBio (IBRX) experienced strong upward price momentum accompanied by…
IBRX Stock Extends Rally As Traders Focus On Oncology Catalysts
ImmunityBio Inc. stocks have been trading up by 7.87 percent following upbeat sentiment around its latest cancer therapy progress. Key Takeaways Shares are up 12.4%, or $1.15, with ImmunityBio recently trading near $10.43 after a string of…
Scientists Uncover Why Esophageal Cancer Shrugs Off PD-1 Blockade
A new study shows that the protein SIRPα, produced by esophageal cancer cells themselves, fuels both tumor growth and T-cell exhaustion, explaining resistance to anti-PD-1 immunotherapy and pointing to a combination strategy.
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA...
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON,…
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
PRINCETON, N.J., Oct. 06, 2026 -- PDS Biotechnology Corporation , a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that...
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
HepaRegeniX to seamlessly advance darizmetinib’s clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 – HepaRegeniX GmbH (“HepaRegeniX”)… HepaRegeniX Completes Darizmetinib…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
tradingview.com3
-
markets.businessinsider.com2
-
bioengineer.org1
-
finance.yahoo.com1
-
heparegenix.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.